Pharmacological targeting of V-ATPase activity by nanomolar concentrations of the macrolide antibiotic bafilomycin A1 resulted in a four-fold decreased release of HSP90α in the conditioned medium by breast cancer cells. This evidence concerns the gene HSP90AA1 and breast cancer.